Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

Ocvirk, Janja; Reberšek, Martina

doi:10.2478/v10019-008-0022-4

Cited by 27 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin K Vitamin K3 (menadione) has a potential role in activating EGFR signalling for human skin keratinocyte cells and A431 human squamous carcinoma cells in vitro in a dose-dependent manner (81). There is an uncontrolled clinical trial to investigate the treatment usage of the topical vitamin K cream for EGFR monoclonal antibody-associated skin toxicity (82).…”

Section: Retinoidmentioning

confidence: 99%

Skin problems and EGFR-tyrosine kinase inhibitor

Kozuki

2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Epidermal growth factor receptor inhibition is a good target for the treatment of lung, colon, pancreatic and head and neck cancers. Epidermal growth factor receptor-tyrosine kinase inhibitor was first approved for the treatment of advanced lung cancer in 2002. Epidermal growth factor receptortyrosine kinase inhibitor plays an essential role in the treatment of cancer, especially for patients harbouring epidermal growth factor receptor activating mutation. Hence, skin toxicity is the most concerning issue for the epidermal growth factor receptor-tyrosine kinase inhibitor treatment. Skin toxicity is bothersome and sometimes affects the quality of life and treatment compliance. Thus, it is important for physicians to understand the background and how to manage epidermal growth factor receptor-tyrosine kinase inhibitor-associated skin toxicity. Here, the author reviewed the mechanism and upfront preventive and reactive treatments for epidermal growth factor receptor inhibitor-associated skin toxicities.

show abstract

Section: Retinoidmentioning

confidence: 99%

Skin problems and EGFR-tyrosine kinase inhibitor

Kozuki

2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

show abstract

“…These include vitamin K, and in particular vitamin K1 (fillochinone) and K3 (menadione). [27][28][29][30][31][32][33][34][35]52,53 Early data on antibiotic prophylaxis also indicate a positive role of tetracyclines. [37][38][39][40][41] The updated Expert Opinion detailed in this article represents the second Italian consensus positions derived from best clinical practices and from the available scientific literature on the treatment of anti-EGFR skin reactions.…”

Section: Antibioticsmentioning

confidence: 98%

Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy

Pinto¹,

Barone

Girolomoni

et al. 2016

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…The adverse effects of treatment with cetuximab are allergic and skin reactions that can be managed. 19 It was also proved that the patients with grade II skin reactions are more likely to respond to treatment. 19,20 The efficiency and safety of cetuximab applied in combination with irinotecan in the patients refractory to chemotherapy was demonstrated also in the multicentric studies MABEL 21 and LABEL.…”

Section: New Target Drugsmentioning

confidence: 99%

“…19 It was also proved that the patients with grade II skin reactions are more likely to respond to treatment. 19,20 The efficiency and safety of cetuximab applied in combination with irinotecan in the patients refractory to chemotherapy was demonstrated also in the multicentric studies MABEL 21 and LABEL. 22 Most valuable data were provided also by the recent studies that were followed by phase II trials, which all support the comparability and consistency of the obtained results.…”

Section: New Target Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Advances in the treatment of metastatic colorectal carcinoma

Ocvirk¹

2009

Radiology and Oncology

Self Cite

View full text Add to dashboard Cite

Background. In most cases, metastatic colorectal cancer is incurable; however, the prognosis and survival of these patients have significantly improved in the last 6 years. A few years back, the only efficient drug for colorectal carcinoma, 5-fluoruracil, yielded the mean survival of 10 months, whereas today, the survival rates of 20 months or more may be obtained by using new cytostatics. In the last six years, five new drugs were registered for the treatment of metastatic colorectal cancer. These are three cytostatics (capecitabine, irinotecan, oxaliplatin) and two target drugs (cetuximab and bevacizumab). Conclusions. A combined treatment assures a better quality of life, and longer remissions and overall survival. The combination of cytostatics and target drugs improves particularly the mean survival rate, which may be longer than 30 months. These combinations of drugs used together with surgical treatment of lung and liver metastases may result in complete remission. An important research achievement of this year is the determination of KRAS mutations.The KRAS gene is the first biomarker that predicts how well patients will respond to certain combination of treatment.

show abstract

Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

Abstract: Background. Cetuximab is a chimeric human-murine monoclonal antibody against the epidermal growth factor receptor (EGFR). It has shown activities against multiple malignancies in clinical trials. EGFR-inhibi-

Cited by 27 publications

References 25 publications

Skin problems and EGFR-tyrosine kinase inhibitor

Skin problems and EGFR-tyrosine kinase inhibitor

Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy

Advances in the treatment of metastatic colorectal carcinoma

Contact Info

Product

Resources

About